NYSE:ABBV - AbbVie Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $160.50
  • Forecasted Upside: 14.37 %
  • Number of Analysts: 16
  • Breakdown:
  • 1 Sell Ratings
  • 6 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$140.34
▲ +2.3 (1.67%)

This chart shows the closing price for ABBV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AbbVie Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABBV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABBV

Analyst Price Target is $160.50
▲ +14.37% Upside Potential
This price target is based on 16 analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is $160.50, with a high forecast of $200.00 and a low forecast of $135.00. The average price target represents a 14.37% upside from the last price of $140.34.

This chart shows the closing price for ABBV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 16 contributing investment analysts is to buy stock in AbbVie. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 13 buy ratings
  • 6 hold ratings
  • 1 sell ratings
2/14/2021
  • 0 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 1 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 1 sell ratings
8/13/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 1 sell ratings
11/11/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 1 sell ratings
2/9/2022
  • 0 strong buy ratings
  • 10 buy ratings
  • 5 hold ratings
  • 1 sell ratings
5/10/2022
  • 0 strong buy ratings
  • 10 buy ratings
  • 5 hold ratings
  • 1 sell ratings
7/9/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 1 sell ratings
8/8/2022

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/1/2022Morgan StanleyLower Price TargetOverweight$191.00 ➝ $188.00Low
8/1/2022UBS GroupLower Price TargetNeutral$154.00 ➝ $146.00Low
8/1/2022Atlantic SecuritiesLower Price TargetOverweight ➝ Neutral$178.00 ➝ $162.00Low
7/29/2022Piper SandlerLower Price Target$160.00 ➝ $155.00Low
7/27/2022UBS GroupBoost Price TargetOutperform$154.00Low
7/8/2022Morgan StanleyBoost Price TargetOverweight$188.00 ➝ $191.00N/A
5/23/2022SVB LeerinkInitiated CoverageUnderperform$140.00High
5/6/2022Daiwa Capital MarketsDowngradeOutperform ➝ Neutral$150.00Low
5/2/2022Wells Fargo & CompanyBoost Price Target$165.00 ➝ $200.00Medium
4/25/2022BMO Capital MarketsBoost Price TargetOutperform$161.00 ➝ $174.00Medium
4/12/2022The Goldman Sachs GroupBoost Price TargetNeutral$122.00 ➝ $140.00High
4/12/2022BarclaysBoost Price TargetEqual Weight$150.00 ➝ $174.00High
4/6/2022Morgan StanleyBoost Price TargetOverweight$142.00 ➝ $192.00Medium
3/1/2022CitigroupBoost Price Target$155.00 ➝ $170.00Low
2/28/2022UBS GroupDowngradeBuy ➝ Neutral$129.00 ➝ $147.00Low
2/4/2022MizuhoBoost Price TargetBuy$154.00 ➝ $166.00Low
2/3/2022JPMorgan Chase & Co.Boost Price Target$165.00 ➝ $180.00Low
2/3/2022Bank of AmericaBoost Price TargetNeutral$135.00 ➝ $138.00Medium
2/3/2022The Goldman Sachs GroupBoost Price TargetNeutral$117.00 ➝ $122.00Medium
2/3/2022BMO Capital MarketsBoost Price TargetOutperform$153.00 ➝ $154.00Medium
2/3/2022BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$133.00 ➝ $150.00High
1/27/2022CitigroupBoost Price Target$125.00 ➝ $155.00Medium
1/24/2022Morgan StanleyBoost Price TargetOverweight$124.00 ➝ $142.00Medium
1/20/2022BarclaysBoost Price TargetEqual Weight$118.00 ➝ $133.00High
1/18/2022CowenBoost Price Target$130.00 ➝ $150.00High
1/13/2022Redburn PartnersInitiated CoverageBuyHigh
1/12/2022BMO Capital MarketsBoost Price TargetOutperform$134.00 ➝ $153.00Low
1/5/2022MizuhoBoost Price TargetBuy$132.00 ➝ $154.00Medium
1/3/2022Piper SandlerBoost Price Target$129.00 ➝ $160.00Low
12/17/2021The Goldman Sachs GroupInitiated CoverageNeutral$113.00High
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweight$165.00High
12/7/2021BMO Capital MarketsReiterated RatingBuy$134.00Low
12/7/2021SVB LeerinkReiterated RatingBuyLow
11/24/2021Truist FinancialBoost Price TargetBuy$118.00 ➝ $135.00Low
11/23/2021Societe GeneraleUpgradeHold ➝ BuyHigh
11/1/2021BarclaysBoost Price TargetEqual Weight$112.00 ➝ $118.00Low
11/1/2021SVB LeerinkLower Price TargetOutperform$142.00 ➝ $135.00Low
11/1/2021Morgan StanleyBoost Price TargetOverweight$116.00 ➝ $124.00Low
10/29/2021Piper SandlerBoost Price TargetOverweight$124.00 ➝ $129.00Low
9/2/2021SVB LeerinkLower Price TargetOutperform$148.00 ➝ $142.00Medium
8/23/2021CowenBoost Price TargetOutperform$120.00 ➝ $130.00Low
8/20/2021Morgan StanleyReiterated RatingBuy$116.00Low
8/20/2021SVB LeerinkBoost Price TargetOutperform$145.00 ➝ $148.00Low
8/5/2021ArgusBoost Price TargetBuy ➝ Buy$130.00 ➝ $140.00Low
8/2/2021SVB LeerinkBoost Price TargetOutperform$144.00 ➝ $145.00Medium
8/2/2021MizuhoBoost Price TargetBuy$128.00 ➝ $131.00Medium
8/2/2021BarclaysBoost Price TargetEqual Weight$105.00 ➝ $112.00Medium
7/27/2021Truist FinancialInitiated CoverageBuy$117.00Low
7/2/2021Daiwa Capital MarketsInitiated CoverageOutperformLow
5/3/2021BMO Capital MarketsBoost Price TargetOutperform$127.00 ➝ $129.00High
5/3/2021MizuhoBoost Price TargetBuy$126.00 ➝ $128.00High
4/30/2021Piper SandlerBoost Price TargetOverweight$120.00 ➝ $124.00Low
4/7/2021Royal Bank of CanadaInitiated Coverage$135.00Low
3/30/2021SVB LeerinkBoost Price TargetOutperform$140.00 ➝ $144.00Low
2/4/2021SVB LeerinkBoost Price TargetIn-Line ➝ Outperform$128.00 ➝ $140.00Low
2/4/2021Royal Bank of CanadaBoost Price TargetOutperform$129.00 ➝ $135.00Low
2/4/2021MizuhoBoost Price TargetBuy$117.00 ➝ $126.00Low
1/28/2021Morgan StanleyLower Price TargetOverweight$120.00 ➝ $116.00Medium
12/16/2020SVB LeerinkBoost Price TargetOutperform$119.00 ➝ $128.00Medium
12/15/2020MizuhoBoost Price Target$111.00 ➝ $117.00Medium
11/30/2020Morgan StanleyBoost Price TargetPositive ➝ Overweight$108.00 ➝ $120.00Low
11/18/2020BMO Capital MarketsInitiated CoverageOutperform$123.00 ➝ $123.00Medium
11/10/2020Sanford C. BernsteinInitiated CoverageOutperform$120.00High
11/2/2020SVB LeerinkLower Price TargetOutperform$122.00 ➝ $119.00High
10/23/2020Truist FinancialInitiated CoverageBuy$110.00Low
10/20/2020The Goldman Sachs GroupDowngradeNeutral ➝ SellHigh
10/16/2020JPMorgan Chase & Co.Boost Price TargetOverweight$115.00 ➝ $120.00Low
9/29/2020Berenberg BankInitiated CoverageHold$98.00Low
9/27/2020MizuhoReiterated RatingBuy$111.00Low
9/2/2020CitigroupBoost Price TargetBuy$98.00 ➝ $105.00Medium
8/20/2020Morgan StanleyBoost Price TargetOverweight$95.00 ➝ $108.00Medium
8/3/2020MizuhoBoost Price TargetBuy$110.00 ➝ $111.00Low
8/3/2020Royal Bank of CanadaBoost Price TargetOutperform$125.00 ➝ $127.00Low
6/29/2020MizuhoBoost Price TargetTop Pick ➝ Buy$101.00 ➝ $110.00Low
6/25/2020Royal Bank of CanadaBoost Price TargetOutperform$102.00 ➝ $125.00Medium
6/23/2020Atlantic SecuritiesUpgradeNeutral ➝ Overweight$115.00Medium
6/18/2020Royal Bank of CanadaReiterated RatingBuy$102.00Low
6/17/2020UBS GroupBoost Price Target$96.00 ➝ $109.00Low
6/10/2020Evercore ISIInitiated CoverageBuy$111.00High
6/10/2020Piper SandlerBoost Price Target$97.00 ➝ $110.00High
6/9/2020Wolfe ResearchUpgradePeer Perform ➝ OutperformLow
6/2/2020ArgusUpgradeHold ➝ Buy$91.40 ➝ $115.00Low
5/28/2020Royal Bank of CanadaReiterated RatingBuy$102.00Low
5/18/2020Bank of AmericaInitiated CoverageNeutral$95.00Low
5/12/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$105.00Medium
5/11/2020Morgan StanleyReiterated RatingOverweight$95.00High
5/11/2020SVB LeerinkBoost Price TargetOutperform$107.00 ➝ $122.00High
5/4/2020SVB LeerinkBoost Price TargetOutperform$103.00 ➝ $107.00Low
5/1/2020MizuhoReiterated RatingBuy$100.00Medium
4/20/2020Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$79.00 ➝ $93.00Low
4/13/2020UBS GroupLower Price TargetBuy$106.00 ➝ $96.00Low
4/12/2020Royal Bank of CanadaReiterated RatingHold$79.00Low
3/23/2020Societe GeneraleDowngradeBuy ➝ HoldHigh
2/27/2020BarclaysInitiated CoverageEqual Weight$97.00 ➝ $97.00High
2/18/2020CowenBoost Price TargetOutperform$98.00 ➝ $105.00Low
2/10/2020MizuhoBoost Price Target$96.00 ➝ $104.00High
2/7/2020Piper SandlerBoost Price TargetOverweight$95.00 ➝ $97.00Low
2/5/2020MizuhoInitiated CoverageBuy$96.00 ➝ $96.00Low
1/23/2020Royal Bank of CanadaReiterated RatingHold$86.00High
1/6/2020Royal Bank of CanadaInitiated CoverageSector Perform$86.00Low
1/3/2020Bank of AmericaDowngradeBuy ➝ NeutralLow
12/26/2019CowenBoost Price TargetOutperform$90.00 ➝ $98.00Low
11/20/2019CitigroupBoost Price TargetBuy$90.00 ➝ $98.00Medium
11/19/2019UBS GroupBoost Price TargetBuy$79.00 ➝ $96.00High
11/1/2019Piper Jaffray CompaniesBoost Price Target$81.00 ➝ $90.00High
9/26/2019CitigroupUpgradeNeutral ➝ Buy$87.00 ➝ $90.00Medium
9/24/2019CowenSet Price TargetBuy$90.00Low
9/12/2019UBS GroupUpgradeNeutral ➝ Buy$85.00 ➝ $79.00Low
9/4/2019Piper Jaffray CompaniesBoost Price TargetOverweight$80.00 ➝ $81.00Medium
8/20/2019Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$80.00High
7/26/2019Piper Jaffray CompaniesSet Price TargetHold$80.00N/A
7/2/2019SVB LeerinkUpgradeBuyLow
6/27/2019Wolfe ResearchUpgradeUnderperform ➝ Peer PerformMedium
6/26/2019CitigroupReiterated RatingHoldMedium
6/26/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$88.00High
5/28/2019The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$84.00High
4/28/2019BMO Capital MarketsUpgradeUnderperform ➝ Market Perform$71.00 ➝ $79.00Low
4/26/2019Credit Suisse GroupSet Price TargetSell$78.00Low
3/25/2019ArgusDowngradeBuy ➝ HoldLow
2/14/2019BarclaysReiterated RatingHold$86.00Low
1/25/2019Credit Suisse GroupSet Price TargetHold$79.00High
1/23/2019UBS GroupReiterated RatingNeutral ➝ Neutral$97.00 ➝ $91.00Low
1/17/2019Credit Suisse GroupUpgradeHold$79.00Medium
1/3/2019Bank of AmericaDowngradeBuy ➝ NeutralMedium
12/26/2018Standpoint ResearchInitiated CoverageBuy ➝ BuyHigh
12/20/2018Morgan StanleySet Price TargetHold$88.00High
11/6/2018ArgusLower Price TargetBuy ➝ Buy$130.00 ➝ $115.00Low
11/5/2018BMO Capital MarketsLower Price TargetUnderperform ➝ Underperform$78.00 ➝ $71.00Low
11/4/2018BarclaysReiterated RatingHold$90.00High
11/2/2018Credit Suisse GroupSet Price TargetHold$85.00High
10/23/2018Wolfe ResearchInitiated CoverageUnderperformLow
10/22/2018SunTrust BanksLower Price TargetBuy ➝ Buy$157.00 ➝ $135.00High
10/20/2018Credit Suisse GroupSet Price TargetSell$85.00High
10/14/2018Credit Suisse GroupSet Price TargetHold$85.00Medium
10/4/2018Bank of AmericaLower Price TargetBuy ➝ Buy$107.00 ➝ $106.00Medium
8/22/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$105.00 ➝ $107.00Low
8/22/2018BMO Capital MarketsReiterated RatingSell$78.00Low
7/30/2018Bank of AmericaLower Price TargetBuy ➝ Buy$112.00 ➝ $105.00Medium
7/27/2018Piper Jaffray CompaniesReiterated RatingHold$100.00Low
7/27/2018CowenSet Price TargetBuy$110.00Low
7/27/2018BMO Capital MarketsReiterated RatingSell$78.00Low
7/15/2018Jefferies Financial GroupSet Price TargetBuy$100.00Low
7/13/2018Credit Suisse GroupUpgradeHold$89.00Low
7/12/2018Berenberg BankInitiated CoverageHold$105.00Low
6/11/2018ArgusLower Price TargetBuy ➝ Buy$145.00 ➝ $130.00Low
6/6/2018Credit Suisse GroupSet Price TargetSell$89.00Low
6/1/2018Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$125.86 ➝ $66.62Low
5/30/2018Deutsche Bank AktiengesellschaftDowngradeNeutral ➝ Underperform$125.86 ➝ $65.61Medium
5/30/2018Deutsche Bank AktiengesellschaftDowngradeNeutral ➝ Underperform$125.86 ➝ $65.61Low
5/29/2018Credit Suisse GroupDowngradeNeutral ➝ Sell$104.00 ➝ $89.00Medium
5/24/2018The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyHigh
5/23/2018BMO Capital MarketsLower Price TargetUnderperform ➝ Underperform$81.00 ➝ $78.00Low
5/1/2018BMO Capital MarketsReiterated RatingSell$81.00Low
4/30/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$131.00 ➝ $110.00High
4/27/2018Credit Suisse GroupLower Price TargetNeutral ➝ Neutral$109.00 ➝ $104.00Medium
4/22/2018Credit Suisse GroupSet Price TargetHold$109.00Low
4/13/2018Jefferies Financial GroupSet Price TargetBuy$122.00Low
4/10/2018Credit Suisse GroupSet Price TargetHold$109.00Low
4/5/2018BarclaysLower Price TargetEqual Weight ➝ Equal Weight$120.00 ➝ $102.00Low
4/5/2018BMO Capital MarketsReiterated RatingSell$80.00Low
3/26/2018Bank of AmericaSet Price TargetHold$120.00High
3/23/2018Jefferies Financial GroupSet Price TargetBuy$125.00High
3/23/2018Credit Suisse GroupLower Price TargetNeutral$109.00 ➝ $98.10Medium
3/23/2018BMO Capital MarketsLower Price TargetUnderperform ➝ Underperform$95.00 ➝ $80.00Medium
3/22/2018BMO Capital MarketsSet Price TargetSell$95.00High
3/13/2018BMO Capital MarketsSet Price TargetSell$95.00Low
2/26/2018Jefferies Financial GroupSet Price TargetBuy$145.00Low
2/21/2018BMO Capital MarketsSet Price TargetSell$95.00Low
2/15/2018BMO Capital MarketsReiterated RatingSell$95.00High
2/15/2018Piper Jaffray CompaniesBoost Price TargetOverweight$130.00 ➝ $138.00High
2/2/2018ArgusBoost Price TargetBuy$120.00 ➝ $145.00Low
1/30/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$99.00 ➝ $131.00Low
1/29/2018Evercore ISIReiterated RatingBuy$144.00Low
1/29/2018Credit Suisse GroupSet Price TargetHold$98.00 ➝ $135.00Medium
1/29/2018BMO Capital MarketsDowngradeMarket Perform ➝ Underperform$125.86 ➝ $84.00Low
1/29/2018SunTrust BanksBoost Price TargetBuy ➝ Average$157.00Low
1/29/2018SVB LeerinkDowngradeOutperform ➝ Market Perform$127.00Medium
1/26/2018Piper Jaffray CompaniesBoost Price TargetOutperform$115.00 ➝ $130.00Low
1/22/2018Credit Suisse GroupSet Price TargetHold$98.00Low
1/11/2018BMO Capital MarketsSet Price TargetHold$84.00Low
1/4/2018Jefferies Financial GroupBoost Price TargetBuy$115.00 ➝ $120.00Low
1/2/2018Piper Jaffray CompaniesReiterated RatingBuyHigh
12/20/2017BMO Capital MarketsSet Price TargetHold$84.00Medium
12/5/2017SVB LeerinkSet Price TargetBuy$106.00Low
12/4/2017BMO Capital MarketsSet Price TargetHold$84.00Low
11/21/2017BMO Capital MarketsReiterated RatingHold$84.00N/A
11/21/2017Societe GeneraleBoost Price TargetN/A
10/30/2017SunTrust BanksReiterated RatingBuyN/A
10/30/2017SVB LeerinkLower Price TargetOutperform$108.00 ➝ $107.00N/A
10/27/2017BMO Capital MarketsSet Price TargetHold$66.00N/A
10/27/2017Piper Jaffray CompaniesBoost Price TargetOverweight$115.00N/A
10/16/2017Jefferies Financial GroupBoost Price TargetBuy$107.00 ➝ $115.00N/A
10/13/2017BarclaysBoost Price TargetEqual Weight$90.00N/A
10/13/2017UBS GroupReiterated RatingNeutralN/A
10/11/2017CowenUpgradeMarket Perform ➝ Outperform$91.17 ➝ $105.00N/A
10/2/2017SVB LeerinkUpgradeMarket Perform ➝ Outperform$89.00 ➝ $106.00Medium
10/1/2017Credit Suisse GroupReiterated RatingNeutral$74.00 ➝ $94.00Medium
9/30/2017Evercore ISIReiterated RatingOutperform$95.00 ➝ $100.00Medium
9/29/2017ArgusBoost Price TargetBuy$90.00 ➝ $110.00Low
9/29/2017Morgan StanleyBoost Price TargetEqual Weight$70.00 ➝ $95.00Low
9/28/2017BarclaysReiterated RatingHold$68.00Low
9/28/2017BMO Capital MarketsReiterated RatingHold$66.00Low
9/28/2017Deutsche Bank AktiengesellschaftBoost Price TargetHold$88.00Low
9/28/2017Jefferies Financial GroupReiterated RatingBuy$107.00Medium
9/25/2017UBS GroupDowngradeBuy ➝ Neutral$79.00 ➝ $92.00Low
9/15/2017Jefferies Financial GroupReiterated RatingBuy ➝ Buy$94.00 ➝ $107.00High
9/15/2017Piper Jaffray CompaniesReiterated RatingBuy$100.00High
9/13/2017SunTrust BanksReiterated RatingBuy$95.00Low
9/12/2017SVB LeerinkReiterated RatingMarket PerformLow
9/11/2017CowenReiterated RatingMarket Perform ➝ Hold$70.00 ➝ $95.00Medium
9/8/2017The Goldman Sachs GroupReiterated RatingBuy$85.00 ➝ $100.00Low
9/8/2017Jefferies Financial GroupReiterated RatingBuy$94.00Low
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$95.00Medium
(Data available from 8/9/2017 forward)

News Sentiment Rating

0.47 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 19 very positive mentions
  • 47 positive mentions
  • 4 negative mentions
  • 5 very negative mentions
1/10/2022
  • 28 very positive mentions
  • 62 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
2/9/2022
  • 16 very positive mentions
  • 65 positive mentions
  • 5 negative mentions
  • 8 very negative mentions
3/11/2022
  • 14 very positive mentions
  • 35 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
4/10/2022
  • 17 very positive mentions
  • 51 positive mentions
  • 10 negative mentions
  • 1 very negative mentions
5/10/2022
  • 15 very positive mentions
  • 35 positive mentions
  • 6 negative mentions
  • 5 very negative mentions
6/9/2022
  • 24 very positive mentions
  • 17 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
7/9/2022
  • 29 very positive mentions
  • 70 positive mentions
  • 8 negative mentions
  • 0 very negative mentions
8/8/2022

Current Sentiment

  • 29 very positive mentions
  • 70 positive mentions
  • 8 negative mentions
  • 0 very negative mentions
AbbVie logo
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More

Today's Range

Now: $140.34
Low: $137.77
High: $140.80

50 Day Range

MA: $147.32
Low: $137.62
High: $154.14

52 Week Range

Now: $140.34
Low: $105.56
High: $175.91

Volume

4,626,296 shs

Average Volume

6,117,487 shs

Market Capitalization

$248.14 billion

P/E Ratio

19.88

Dividend Yield

4.09%

Beta

0.7

Frequently Asked Questions

What sell-side analysts currently cover shares of AbbVie?

The following sell-side analysts have issued research reports on AbbVie in the last year: Atlantic Securities, Bank of America Co., Barclays PLC, BMO Capital Markets, Citigroup Inc., Cowen Inc, Daiwa Capital Markets, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Piper Sandler, Redburn Partners, Societe Generale, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., Truist Financial Co., UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for ABBV.

What is the current price target for AbbVie?

16 Wall Street analysts have set twelve-month price targets for AbbVie in the last year. Their average twelve-month price target is $160.50, suggesting a possible upside of 14.4%. Wells Fargo & Company has the highest price target set, predicting ABBV will reach $200.00 in the next twelve months. Truist Financial Co. has the lowest price target set, forecasting a price of $135.00 for AbbVie in the next year.
View the latest price targets for ABBV.

What is the current consensus analyst rating for AbbVie?

AbbVie currently has 1 sell rating, 6 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ABBV will outperform the market and that investors should add to their positions of AbbVie.
View the latest ratings for ABBV.

What other companies compete with AbbVie?

How do I contact AbbVie's investor relations team?

AbbVie's physical mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company's listed phone number is (847) 932-7900. The official website for AbbVie is www.abbvie.com. Learn More about contacing AbbVie investor relations.